22 October 2018
MSD Animal Health launches BRAVECTO® Plus spot-on solution For Cats New Product Shows Effectiveness in Ticks and Fleas for 12 Weeks and Prevents Heartworm Disease for 8 Weeks
UK, October 22nd, 2018 – MSD Animal Health has announced the launch of BRAVECTO® Plus in the UK, a topical solution for cats with, or at risk from external and internal parasite infestations.
BRAVECTO Plus is a sustained, broad-spectrum combination (fluralaner plus moxidectin) topical solution for cats, protecting against ticks and fleas, and infestations of heartworm, intestinal roundworm and hookworm.
The product contains fluralaner (280 mg/ml), an ectoparasiticide which provides systemic activity against ticks and fleas, and moxidectin (14 mg/ml), an endectocide which provides systemic activity against a range of internal worms.
BRAVECTO® Plus is applied topically using the “Twist’n’Use” pipette. Once applied, the product provides immediate and persistent tick (lxodes ricinus) and flea (Ctenocephalides felis) killing activity for 12 weeks, while also treating intestinal roundworm and hookworm and preventing heartworm disease caused by Dirofilaria immitis for eight weeks.
BRAVECTO® Plus can also be used as part of a treatment strategy for flea allergy dermatitis.
BRAVECTO® was launched in 2014 as a chewable tablet for dogs, and, in 2016 BRAVECTO® spot-on was launched as a topical solution for dogs and cats. More than 80 million doses of BRAVECTO® have been distributed in 72 countries since its introduction.
Amanda Melvin, marketing manager, at MSD Animal Health, said: “These parasites are not just a nuisance, but also pose animal and human health risks, as ticks and fleas can transmit disease.
“We are pleased to introduce the latest innovation in feline parasite protection to the BRAVECTO® family.”
For more information, please refer to the summary of product characteristics or contact your MSD account manager.
About MSD Animal Health
For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of MSD. Through its commitment to the Science of Healthier Animals®, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com or connect with us on LinkedIn and Twitter.
BRAVECTO® Plus contains fluralaner and moxidectin. It is indicated for cats with, or at risk from, mixed parasitic infestations by ticks and fleas, gastrointestinal nematodes or heartworm. Refer to the packaging or package leaflet for information about side effects, precautions, warnings and contraindications. Further information is available from the SPC / Datasheet or Intervet UK Ltd trading as MSD Animal Health. Registered office Walton Manor, Walton, Milton Keynes MK7 7AJ, UK. Registered in England & Wales no. 946942.
Use medicines responsibly. For more information please refer to the NOAH website.